Status:
UNKNOWN
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Lead Sponsor:
Scientific Institute San Raffaele
Conditions:
Atrial Fibrillation
Myocardial Infarction
Eligibility:
All Genders
18+ years
Brief Summary
Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antit...
Detailed Description
INTRODUCTION The optimal antithrombotic therapy (combination of anticoagulants and antiplatelets drugs) for patients with non valvular atrial fibrillation (NVAF) after coronary stenting is unknown. In...
Eligibility Criteria
Inclusion
- • Patients aged 18 years or older
- Patients with a diagnosis of non valvular atrial fibrillation (or atrial flutter treated) with PCI and stent (drug eluting or bare metal stent) requiring triple antithrombotic therapy (double antiplatelets agents and oral anticoagulation) or dual antithrombotic therapy (single antiplatelet agent and oral anticoagulation)
- Patients with NVAF treated for elective PCI (in the contest of chronic coronary syndromes) or urgent (in the contest of an acute coronary syndromes: STEMI, NSTEMI, unstable angina).
- Patients who give the informed consent.
Exclusion
- • Patients with less than 6 months of clinical follow-up availability
Key Trial Info
Start Date :
January 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04291287
Start Date
January 25 2020
End Date
September 30 2022
Last Update
March 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cosmo Godino
Milan, Italy, 20131